Results 1 to 10 of about 3,163,017 (221)

Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis. [PDF]

Front Endocrinol (Lausanne), 2017
With the increased pro-inflammatory response in both rheumatoid arthritis and thyroid autoimmune diseases, treatment with biological antirheumatic agents (BAAs) of the former may affect the course of the latter.
Bliddal S, Borresen SW, Feldt-Rasmussen U.   +2 more
europepmc   +10 more sources

Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents [PDF]

Medicina, 2022
Systemic inflammation represents a shared pathophysiological mechanism which underlies the frequent clinical associations among chronic inflammatory rheumatic diseases (CIRDs), insulin resistance, type 2 diabetes (T2D), and chronic diabetes complications,
Marco Infante, Nathalia Padilla, Rodolfo Alejandro, Massimiliano Caprio, David Della-Morte, Andrea Fabbri, Camillo Ricordi   +6 more
doaj   +6 more sources

Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents. [PDF]

JAMA Netw Open, 2022
Key Points Question Is use of targeted disease-modifying antirheumatic drugs associated with risk of Alzheimer disease and related dementia (ADRD)? Findings In this cohort study including 22 569 propensity score–matched patient pairs, initiation of ...
Desai RJ, Varma VR, Gerhard T, Segal J, Mahesri M, Chin K, Horton DB, Kim SC, Schneeweiss S, Thambisetty M.   +9 more
europepmc   +3 more sources

Effects of antirheumatic agents on cytokines [PDF]

Seminars in Arthritis and Rheumatism, 1996
A review of the literature concerning the effects of traditional antirheumatic drugs on cytokines and the cytokine and anticytokine approaches already used in the therapy of rheumatoid arthritis (RA) is presented. Many antirheumatic drugs are capable of cytokine modulation in vitro. Corticosteroids inhibit the transcription of a broad spectrum of genes
Pilar Barrera, A M Boerbooms, Leo B. A. Van De Putte, J.W.M. van der Meer   +3 more
semanticscholar   +7 more sources

Studies on antirheumatic agents. 3-Benzoylpropionic acid derivatives.

Chemical and Pharmaceutical Bulletin, 1988
As part of the search for new antirheumatic agents, three types of 3-benzoylpropionic acid derivatives having a mercapto moiety in their structures were prepared, and tested for suppressing activity on adjuvant arthritis in Sprague-Dawley rats.
Kazuya Kameo, Kunio Ogawa, Kimiyo Takeshita, Shiro Nakaike, Kazuyuki Tomisawa, K. SOTA   +5 more
semanticscholar   +7 more sources

Antirheumatic Agents. I. Novel Methotrexate Derivatives Bearing an Indoline Moiety.

Chemical and Pharmaceutical Bulletin, 1996
Various novel methotrexate (MTX) derivatives bearing an indoline moiety were synthesized and tested for biological activities using human peripheral blood mononuclear cell (hPBMC) and human synovial cells (hSC) derived from patients with rheumatoid ...
Hiroharu Matsuoka, Nobuaki Kato, K. TSUJI, Noriaki Maruyama, Hiroshi Suzuki, Masahiko Mihara, Yasuhisa Takeda, Keiichi Yano   +7 more
semanticscholar   +6 more sources

Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis [PDF]

Journal of Rheumatology, 2017
Objective. To characterize the effect of anti-tumor necrosis factor (TNF) therapy compared to conventional synthetic disease-modifying antirheumatic drugs (csDMARD) in children with enthesitis-related arthritis (ERA) over the first year after diagnosis ...
Pamela F. Weiss, Rui Xiao, Timothy G. Brandon, Ilaria Pagnini, Tracey Wright, Timothy Beukelman, Esi Morgan-DeWitt, Chris Feudtner   +7 more
openalex   +2 more sources

Antirheumatic agents in covid-19: is IL-6 the right target? [PDF]

Annals of the Rheumatic Diseases, 2020
The letter of Monti et al 1 on covid-19 in patients with chronic arthritis treated with immunosuppressive therapies stimulates some considerations.
P. Capecchi, P. Lazzerini, L. Volterrani, M. Mazzei, B. Rossetti, G. Zanelli, D. Bennett, E. Bargagli, F. Franchi, M. Cameli, S. Valente, L. Cantarini, B. Frediani   +12 more
semanticscholar   +5 more sources

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis [PDF]

Arthritis care & research, 2012
The American College of Rheumatology (ACR) most recently published recommendations for use of disease modifying anti-rheumatic drugs (DMARDs) and biologics in the treatment of rheumatoid arthritis (RA) in 2008 (1).
Jasvinder A. Singh, Daniel E. Fürst, Aseem Bharat, Jeffrey R. Curtis, Arthur F. Kavanaugh, Joel M. Kremer, Larry W. Moreland, James R. O’Dell, Kevin Winthrop, Timothy Beukelman, S. Louis Bridges, W. Winn Chatham, Harold E. Paulus, María E. Suárez-Almazor, Claire Bombardier, Maxime Dougados, Dinesh Khanna, Charles M. King, Amye Leong, Eric L. Matteson, John T. Schousboe, Eileen Moynihan, Karen S. Kolba, Archana Jain, Elizabeth R. Volkmann, Harsh Agrawal, Sangmee Bae, Amy S. Mudano, Nivedita M. Patkar, Kenneth G. Saag   +29 more
openalex   +2 more sources

Effect of Benzylidene Derivative (Novel Antirheumatic Agent) on Chondrocyte Metabolism.

Journal of Pharmacobio-Dynamics, 1992
The effects of protocatechualdehyde (PAL), one of the metabolites of 3,4-diacetoxy benzylidene diacetate (ACP), on proteoglycan metabolism and secretion of interleukin 1 (IL-1) like activity (lymphocyte activating factor; LAF activity) were studied using rabbit articular chondrocytes culture under phorbol myristate acetate (PMA) and Ca2+ ionophore ...
Koju Watanabe, Fumihiko Kimura, Masayuki Shinmei   +2 more
openalex   +5 more sources